Curanex Pharmaceuticals Inc
Business
Curanex Pharmaceuticals is a developmental-stage biopharmaceutical company discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a proprietary botanical extract derived from a medicinal plant used in Chinese traditional medicine, in preclinical development for ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company plans IND submission for ulcerative colitis in Q4 2026 and pursues licensing or partnership arrangements.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| General & Administrative | 1 | 290,386 | |
| IP Development Impairments | — | 74,676 | |
| Research & Development | 3 | — | |
| Total Operating Expenses | 4 | 365,062 | |
| Loss from Operations | −4 | −365,062 | |
| Interest Expense | −8,537 | — | |
| Other Income | 22,507 | 3,556 | |
| Net Loss | −4 | −361,506 | |
| Net loss per common share: Basic | −0.17 | −0.03 | |
| Net loss per common share: Diluted | −0.17 | −0.03 | |
| Weighted average number of common shares outstanding: Basic | 25 | 13 | |
| Weighted average number of common shares outstanding: Diluted | 25 | 13 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash | 5 | 148,891 | — | |
| Prepaid Expenses | 6 | 1,179 | — | |
| Other Current Assets | — | 367,865 | — | |
| Total Current Assets | 11 | 517,935 | — | |
| Right-of-Use Asset | 352,616 | — | — | |
| TOTAL ASSETS | 12 | 517,935 | — | |
| Accrued Expenses | 11,915 | 9,575 | — | |
| Accounts Payable | 2,426 | 5,000 | — | |
| Lease Liability, Current | 122,689 | — | — | |
| Total Current Liabilities | 137,030 | 14,575 | — | |
| Lease Liability, Noncurrent | 224,010 | — | — | |
| TOTAL LIABILITIES | 361,040 | 14,575 | — | |
| Common Stock, 475,000,000 Shares Authorized; $0.0001 par Value; 28,340,812 Shares Issued and Outstanding as of December 31, 2025, and 24,000,000 December 31, 2024 | 2,834 | 2,400 | — | |
| Preferred Stock, 25,000,000 Shares Authorized; $0.0001 par Value; 1,000,000 Shares Issued and Outstanding as of December 31, 2025, and December 31, 2024 | 100 | 100 | — | |
| Common Stock to be Issued | — | 200,000 | — | |
| Additional Paid-in Capital | 16 | 923,309 | — | |
| Accumulated Deficit | −5 | −622,449 | — | |
| TOTAL SHAREHOLDERS EQUITY | 11 | 503,360 | 60,090 | |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | 12 | 517,935 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Amortization of Right-of-Use Assets | 79,396 | — | |
| IP Development Impairments | — | 74,676 | |
| Prepaid Expenses | −6 | −1,179 | |
| Lease Liabilities | −85,210 | — | |
| Accounts Payable | −2,574 | 5,000 | |
| Accrued Expenses | 2,340 | −4,701 | |
| Other Current Assets | — | −267,865 | |
| NET CASH USED IN OPERATING ACTIVITIES | −10 | −555,575 | |
| Issuance of Common Stock Private Placements | — | 630,000 | |
| Issuance of Preferred Stock | — | 100 | |
| Proceeds from Issuance of Common Stock, net of Underwriting Costs - IPO | 16 | — | |
| Payment of Offering Costs | −346,497 | — | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 15 | 630,100 | |
| NET INCREASE IN CASH | 5 | 74,525 | |
| Issuance of Common Stock with Non-cash Payment | — | 100,000 | |
| Recognition of Right-of-Use Asset in Exchange for Lease Liability | 323,820 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Curanex Pharmaceuticals Inc's CIK number?
Curanex Pharmaceuticals Inc's SEC CIK number is 0002025942 (2025942). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Curanex Pharmaceuticals Inc's SEC filings?
All of Curanex Pharmaceuticals Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.